Search Results

Analyzing individual cancer cells has enabled Stanford researchers to identify the small population of cells that spur relapse in some children with leukemia.

Elevated maternal blood sugar when the fetal heart is forming has been linked to a heightened risk for congenital heart defects, according to a new Stanford study.

High-grade gliomas, a group of aggressive brain tumors, cease growing in mice if a signaling molecule called neuroligin-3 is absent or its activity is blocked with drugs, a Stanford team has shown.

The new Stanford Center for Definitive and Curative Medicine will work to turn discoveries into stem cell and gene therapies to aid the millions of people who have genetic diseases.

Targeting backup biological pathways often used by cancers can lead to more efficient drug development and less-toxic therapies. Stanford researchers have developed a new way to identify these pathways.

Pretreatment with a stem-cell-activating protein significantly enhances healing in mice, Stanford researchers say. The approach could eventually help people going into surgery or combat heal better from injuries they sustain.

Stanford researchers have developed a test that may help screen for cardiotoxicity in new chemotherapy drugs.

Microfluidics, electronics and inkjet technology underlie a newly developed all-in-one biochip from Stanford that can analyze cells for research and clinical applications.

Effective anti-tumor activity requires a systemic, rather than only a local, immune response at the tumor site. A Stanford study may help clinicians pinpoint why only some cancer patients respond to immunotherapies.

Monitoring cancer DNA in blood can predict recurrence and prognosis and drive treatment decisions. A Stanford study of 92 lymphoma patients suggests similar techniques may work for other tumors.